[Silica-containing urinary stones--clinical issues to keep in mind].
Formation of calculi in efferent urinary passages is always due to supersaturation of urinary calculi substances and associated increased crystallization. Apart from the typical calculi, consisting of calcium oxalate, inorganic phosphates, uric acid or cystine, there are occasional signs of rare substance classes. Although more than 50 silicate stones have already been reported internationally, this stone entity remains relatively unknown. In particular, the occurrence of silicate stones in the absence of magnesium trisilicate abuse is extremely rare. A medium-sized left-sided ureterolith was removed from a 54-year-old male patient using a ureteroscope. X-ray diffraction showed it to be a compound stone consisting of 40% silicate. The patient, who in 1986 was living close to the nuclear reactor accident in Chernobyl, showed no signs of a constant uptake of magnesium trisilicate. However, he had undergone partial (2/3) gastrectomy 4 months before for a drug-refractory gastric ulcer, which had been diagnosed at the end of the 1980s and treated with excessive dosages of a magnesium trisilicate antacid preparation until the time of the operation. The patient had also been suffering from unstable angina pectoris since 1986 and treated with Pentalong (pentaerythrityltetranitrate) for 17 years. We were also able to detect silicium dioxide in components of this drug using X-ray diffraction. Silicate uroliths are extremely rare but they can be clearly identified by X-ray diffraction or infrared spectroscopy and distinguished from artifacts or quartz pebbles. Formation of calculi can be prevented by increasing diuresis as well as switching to a different drug and reducing the dosage.
May
M
M
Urologische Klinik, Carl-Thiem-Klinikum, Cottbus. M.May@ctk.de
Helke
C
C
Kubenz
K
K
Seehafer
M
M
Wolter
M
M
Hoschke
B
B
D000789:Angina, Unstable / Q000188:drug therapy; D018360:Crystallography, X-Ray; D005743:Gastrectomy; D006801:Humans; D008134:Long-Term Care; D017633:Magnesium Silicates / Q000009:adverse effects* / Q000737:chemistry / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010417:Pentaerythritol Tetranitrate / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use; D012822:Silicon Dioxide / Q000032:analysis*; D013276:Stomach Ulcer / Q000601:surgery; D014514:Ureteral Calculi / Q000139:chemically induced / Q000737:chemistry* / Q000601:surgery; D018666:Ureteroscopy
D017633:Magnesium Silicates; D010417:Pentaerythritol Tetranitrate; C100210:pentrinitrol; D012822:Silicon Dioxide; C001671:magnesium trisilicate